Item(by='m-ee', descendants=None, kids=[25964325, 25964877], score=None, time=1611960428, title=None, item_type='comment', url=None, parent=25963732, text='It&#x27;s quite literally one of the first things mentioned in the trial protocols and journal articles<p><a href="https:&#x2F;&#x2F;clinicaltrials.gov&#x2F;ct2&#x2F;show&#x2F;NCT04516746" rel="nofollow">https:&#x2F;&#x2F;clinicaltrials.gov&#x2F;ct2&#x2F;show&#x2F;NCT04516746</a><p>&quot;The efficacy of 2 IM doses of AZD1222 compared to placebo for the prevention of COVID-19 in adults ≥ 18 years of age [ Time Frame: 1 year ]<p>A binary response, whereby a participant is defined as a COVID-19 case if their first case of SARS-CoV-2 RT-PCR-positive symptomatic illness occurs<p>≥ 15 days post second dose of study intervention. Otherwise, a participant is not defined as a COVID-19 case.&quot;<p><a href="https:&#x2F;&#x2F;www.thelancet.com&#x2F;journals&#x2F;lancet&#x2F;article&#x2F;PIIS0140-6736(20)32661-1&#x2F;fulltext" rel="nofollow">https:&#x2F;&#x2F;www.thelancet.com&#x2F;journals&#x2F;lancet&#x2F;article&#x2F;PIIS0140-6...</a><p>&quot;The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. &quot;')